Menu
close
Menu
close
Menu
close
Menu
close
Menu
close
Menu
close

Knowledge Hub

Resource Type
Article Spotlight(9)
Blog(35)
Case Studies(21)
Collaterals(6)
Resource Topic
Alamut(5)
BioPharma(11)
Blood Cancers(3)
Genomics(60)
Hereditary Cancers(11)
Liquid Biopsy(3)
Multimodal(5)
Radiomics(2)
Rare & Inherited Disorders(25)
Solid Tumors(22)
10 of 71
 Resources
Blog
The evolving role of exomes and genomes in clinical practice

Discover expert insights on the evolving role of exome and genome sequencing in clinical diagnostics. Learn how virtual panels, reimbursement trends, and technical advancements are shaping genomic medicine.
Case Studies
Customer Spotlight: Jean-Christophe Bernhard & Gaëlle Margue – A collaboration with UroCCR

We sat down with Prof. Jean-Christophe Bernhard, UroCCR Coordinator, and Dr. Gaëlle Margue, Urology Fellow, at University Hospital Bordeaux, to discuss the collaboration between UroCCR – the French Kidney Cancer Research Network - and SOPHiA GENETICS, and get their insights on the use of AI-powered multimodal approaches to improve patient care.
Case Studies
Customer Spotlight: Elexandra Barboza-Arguedas at National Children’s Hospital “Carlos Saenz-Herrera”

We’re excited to shine a spotlight on Elexandra Barboza-Arguedas, who delivered an insightful presentation during our ACMG exhibit theatre session this year. In this interview, she shares deeper insights into her work at the Molecular Diagnostics Laboratory and how the SOPHiA DDM™ Platform is helping her team streamline workflows and uncover critical insights tailored to the unique genetic landscape of the Costa Rican population.
Article Spotlight
Article Spotlight: Addition of radiomic features improves the prediction of lung toxicity occurrence after (Chemo)RT

Discover how adding radiomic features with SOPHiA DDM™ for Radiomics, to clinical and dosimetric data enhances the prediction of acute lung toxicity in patients receiving radiotherapy for lung cancer.
Case Studies
Customer Spotlight: New Generation SOPHiA DDM™ Platform – The University-Hospital of Parma Experience

We were glad to host Dr. Davide Martorana, Senior Molecular Geneticist at the Medical Genetic Lab of the University-Hospital of Parma in Italy, who shared with us his institute’s experience with the adoption of the New Generation SOPHiA DDM™ Platform. Read the spotlight:
Blog
Three steps forward in efficient myeloid biomarker learning

More than six people die every hour in the US from a blood cancer. Solutions can’t come fast enough for those who suffer with these cancers all around the world. Fortunately, researchers studying blood diseases have experienced rapid advances in their capabilities to develop and test effective therapies with some extremely significant advancements.
Blog
How Predictive Analytics is Boosting Clinical Trials Efficiency?

Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a new era of precision efficiency². This blog explores how predictive analytics is transforming clinical trials, from optimizing design and recruitment to predicting outcomes and reducing risks.
Blog
The Importance of Data Diversity to Enhance Clinical Trials Success

Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹⁻³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.
Blog
Matched tumor-normal sequencing: The preferred method for identifying somatic mutations driving tumorigenesis

Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.
Article Spotlight
ECP Posters spotlight

We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company.
10 of 71
 Resources

Here to Help

Got questions? Reach us by phone, email, or through our contact form
Contact Us

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.